Just in case it has been buried in another thread ... thought the video Yankee posted was something we could all watch to get an idea of what Mesoblast is focusing on in 2016.
So CHF/Teva is clearly the big fish MSB have brought on board thus far ... and it sounds like the next big fish is catching a partner for back-pain.
It is very encouraging to hear Michael Schuster explain that MSB's product is being touted as a transformative program for back-pain... generating a lot of excitement in the pain-treatment industry, and that MSB is in advanced stages of discussion with partners. In discussions with Orthopaedic, big pharmas, specialty pharmas ... it doesn't seem MSB will struggle to land this fish! Mesoblast seem to be on a very very strong footing in terms of negotiations... lots of competition and Mesoblast are likely to go with the partner that delivers the best benefits to shareholders.
Enjoy ANZAC day everyone, and don't forget the Appendix 4C is due next week. At the very least, next week we will get an insight into Temcell sales to date and cash-burn rate.
the next big fish... back pain
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
-0.025(2.23%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.16 | $1.04 | $14.57M | 13.49M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 21024 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 241 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |